Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab

The purpose of the study is to find out if an investigational drug called Dendritic Cell (DC1) vaccine added to standard neoadjuvant (given before main treatment) therapy can help people with HER2 (human epidermal growth factor receptor 2) positive breast cancer.

Trial Details

NCT ID

NCT05325632

Phase

PHASE2

Sponsor

H. Lee Moffitt Cancer Center and Research Institute

Status

RECRUITING

Cancer Type

HER2 Positive Breast Cancer

Interventions

HER-2 pulsed DC1
Trastuzumab
Pertuzumab
Paclitaxel
Resection surgery

Locations (sample)

Tampa, Florida, United States|27.94752,-82.45843

Key Eligibility Criteria

Participants must have histologically confirmed clinical stage I- III, HER2+ (per ASCO/CAP criteria) invasive carcinoma of the breast. Primary tumo…
Candidate for neoadjuvant chemotherapy with Paclitaxel, Trastuzumab, Pertuzumab regimen followed by standard of care local therapy as determined by…
Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
Participants must have normal organ and marrow function as defined per protocol.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find HER2 Positive Breast Cancer Trials on Trialify →